Therapeutic effects of endoscopic variceal ligation combined with partial splenic embolization for portal hypertension

Table 1 Clinical characteristics of cirrhotic patients and con-trol subjects

	EVL-PSE group (n = 41)	Control group (n = 40)
Sex:male/female	32/9	29/11
Age:mean,range(years)	43,34-67	37,18-68
Childs’ class:A/B/C	5/26/10	0
Etiology
Viral hepatitis	37	0
Primary biliary cirrhosis	1	0
Schistosomiasis	4	0
Virix grading (III/IV)	14/26
Red color sign	15	0

Table 2 Changes of laboratory parameters after EVL-PSE

	Hemoglobin (g/L)	WBC ( × 109/L)	Platelet ( × 109/L)
Before EVL-PSE	104 ± 14	2.9 ± 0.6	55 ± 11
1 wk after EVL-PSE	117 ± 12	7.4 ± 1.5a	102 ± 18a
2 wk after EVL-PSE	119 ± 16	6.1 ± 1.2a	120 ± 24a

^aP < 0.05 vs before EVL-PSE.

Table 3 Comparison of hemodynamics between cirrhotic patients before EVL-PSE and control group

	Diameter (mm)		Blood flow velocity (cm/s)		Blood flow rate (L/min)
	Controls	PSE-EVL group	Controls	PSE-EVL group	Controls	PSE-EVL group
Portal vein (n = 37)	11.82 ± 1.69	15.51 ± 1.71a	20.19 ± 2.21	15.10 ± 2.78a	1.15 ± 0.20	0.98 ± 0.20a
LGV (n = 36)	3.72 ± 0.79	6.33 ± 1.49a	7.72 ± 1.88	15.71 ± 3.63a	0.06 ± 0.03	0.45 ± 0.19a
Azygos vein (n = 36)	6.00 ± 1.09	10.08 ± 1.17a	16.03 ± 3.01	29.22 ± 6.72a	0.34 ± 0.04	1.20 ± 0.35a

^aP < 0.05 vs control group.

Table 4 Comparison of hemodynamics 1 wk before and after EVL-PSE in cirrhotic patients

	Diameter (mm)		Blood flow velocity (cm/s)		Blood flow rate (L/min)
	Before EVL-PSE	After EVL-PSE	Before EVL-PSE	After EVL-PSE	Before EVL-PSE	After EVL-PSE
Portal vein (n = 40)	15.51 ± 1.71	16.2 ± 1.431	15.10 ± 2.78	13.92 ± 2.74a	0.98 ± 0.20	0.72 ± 0.15b
LGV(n = 35)	6.33 ± 1.49	7.41 ± 1.81	15.71 ± 3.63	12.11 ± 2.79	0.45 ± 0.19	0.44 ± 0.19
Azygos vein (n = 37)	10.08 ± 1.17	7.12 ± 1.22	29.22 ± 6.72	20.11 ± 5.01	1.20 ± 0.35	0.68 ± 0.23

¹P > 0.05,

^aP < 0.05,

^bP < 0.01.